10.20 USD
↘ 0.66 (6.08%)AT CLOSE (03:59 PM EDT)
Xeris Biopharma Holdings, Inc. Common Stock
XERSNASDAQ • USD
10.24
↗ 0.04 (0.39%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
10.24
↗ 0.04 (0.39%)
Market: CLOSED
Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades at $10.20 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (176.3%), a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, XERS trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Oct 23, 2026.
Open?$10.85
High?$10.85
Low?$10.06
Prev. Close?$10.86
Volume?2.4M
Avg. Volume?3.1M
VWAP?$10.30
Rel. Volume?0.77x
Bid / Ask
Bid?$10.19 × 100
Ask?$10.23 × 2.5K
Spread?$0.04
Midpoint?$10.21
Valuation & Ratios
Market Cap?1.9B
Shares Out?N/A
Float?176.1M
Float %?96.6%
P/E Ratio?N/A
P/B Ratio?-191.05
EPS?-$0.09
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Employees
435
Market Cap
1.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-06-21
Address
1375 WEST FULTON STREET, SUITE 1300
CHICAGO, IL 60607
Phone: 844-445-5704
CHICAGO, IL 60607
Phone: 844-445-5704
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?24
Momentum?75
Short Sent.?80
Piotroski F-Score?3/9Weak
Altman Z-Score?1.62Distress
Confidence?60%Moderate
Short InterestLow
Short % of Float?4.09%Low
Short Interest?7.2M
Days to Cover?1.7
Free Float176.1M
Avg Daily Volume4.1M
Settlement Date2026-09-30
Financial Health
Current Ratio?1.45Adequate
Quick Ratio?1.02Adequate
Cash Ratio?0.64Adequate
Debt/Equity?-25.95Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?-191.05CHEAP▾
S&P97
P/S?5.54FAIR▾
Peers100
S&P25
P/FCF?33.4FAIR▾
Peers100
S&P24
EV/EBITDA?40.8HIGH▾
Peers100
S&P5
EV/Sales?5.93FAIR▾
Peers100
S&P28
Returns & Efficiency
ROE?176.3%STRONG▾
Peers50
S&P97
ROA?-4.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$55.7M
Enterprise Value?$2.0B
Fundamentals ratios updated end of day